Drugs / Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01371604 Background | Jul 2011 → Mar 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01371604 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT01371604 ↗ |